Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Novel kinase inhibitors

BRAF inhibitors: Targeting class II/III alterations


07 Mar 2023


Novel kinase inhibitors


Clinical Research;  Translational Research;  Targeted Therapy;  Molecular Oncology;  Genetic and Genomic Testing

Tumour Site


Alison Schram


A. Schram

Author affiliations

  • Medicine Department, MSKCC - Memorial Sloan Kettering Cancer Center, 10065 - New York/US


This content is available to ESMO members and event participants.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.